Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine.

Breadner D, Vincent MD, Jonker D, Cripps C, Klimo P, Biagi J, Lam W, O'Connell A, Whiston F, Stitt L, Welch S.

J Geriatr Oncol. 2018 Nov;9(6):659-664. doi: 10.1016/j.jgo.2018.04.002. Epub 2018 May 2.

PMID:
29728308
2.

Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs.

Dranitsaris G, Zhu X, Adunlin G, Vincent MD.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):351-357. doi: 10.1080/14737167.2018.1467270. Epub 2018 Apr 25. Review.

PMID:
29681201
3.

Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer.

Zhang TW, Rodrigues GB, Louie AV, Palma D, Dar AR, Dingle B, Kocha W, Sanatani M, Yaremko B, Yu E, Younus J, Vincent MD.

Curr Oncol. 2018 Feb;25(1):22-31. doi: 10.347/co.25.3657. Epub 2018 Feb 28.

4.

Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein.

Ferguson PJ, Vincent MD, Koropatnick J.

J Pharmacol Exp Ther. 2018 Jan;364(1):46-54. doi: 10.1124/jpet.117.241661. Epub 2017 Oct 23.

PMID:
29061656
5.

Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype.

Rodic S, Vincent MD.

Int J Cancer. 2018 Feb 1;142(3):440-448. doi: 10.1002/ijc.31069. Epub 2017 Oct 9. Review.

6.

Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.

Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P, Biagi JJ, Lam W, O'Connell A, Whiston F, Stitt L, Welch SA.

Curr Oncol. 2017 Aug;24(4):e261-e268. doi: 10.3747/co.24.3516. Epub 2017 Aug 31.

8.

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Barnes TA, O'Kane GM, Vincent MD, Leighl NB.

Front Oncol. 2017 May 31;7:113. doi: 10.3389/fonc.2017.00113. eCollection 2017. Review.

9.

Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.

Vincent MD, Breadner D, Soulieres D, Kerr IG, Sanatani M, Kocha W, Klimo P, MacKenzie MJ, O'Connell A, Whiston F, Malpage AS, Stitt L, Welch SA.

Future Oncol. 2017 Apr;13(9):777-786. doi: 10.2217/fon-2016-0444. Epub 2017 Jan 3.

PMID:
28045335
10.

Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

Yan M, Ho C, Winquist E, Jonker D, Rayson D, Stitt L, Tokmakejian S, Tomiak A, Vincent MD.

Clin Colorectal Cancer. 2016 Dec;15(4):369-376.e3. doi: 10.1016/j.clcc.2016.06.001. Epub 2016 Jun 23.

PMID:
27474080
11.

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.

Di Cresce C, Figueredo R, Rytelewski M, Maleki Vareki S, Way C, Ferguson PJ, Vincent MD, Koropatnick J.

Oncotarget. 2015 Sep 8;6(26):22397-409.

12.

Promising targets and current clinical trials in metastatic squamous cell lung cancer.

Vincent MD.

Front Oncol. 2014 Dec 9;4:320. doi: 10.3389/fonc.2014.00320. eCollection 2014. Review.

13.

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.

Korpanty GJ, Graham DM, Vincent MD, Leighl NB.

Front Oncol. 2014 Aug 11;4:204. doi: 10.3389/fonc.2014.00204. eCollection 2014. Review.

14.

Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.

Lineweaver CH, Davies PC, Vincent MD.

Bioessays. 2014 Sep;36(9):827-35. doi: 10.1002/bies.201400070. Epub 2014 Jul 14.

15.

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL.

Lung Cancer. 2012 Oct;78(1):76-80. doi: 10.1016/j.lungcan.2012.06.011. Epub 2012 Jul 23.

16.

Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS.

Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S.

Curr Oncol. 2012 Jun;19(Suppl 1):S33-44. doi: 10.3747/co.19.1149.

17.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME.

Ann Oncol. 2012 Aug;23(8):2103-8. doi: 10.1093/annonc/mdr580. Epub 2012 Jan 6.

18.

Cancer: beyond speciation.

Vincent MD.

Adv Cancer Res. 2011;112:283-350. doi: 10.1016/B978-0-12-387688-1.00010-7. Review.

PMID:
21925308
19.

Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed.

Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J.

J Pharmacol Exp Ther. 2011 Sep;338(3):952-63. doi: 10.1124/jpet.111.183178. Epub 2011 Jun 14.

PMID:
21673071
20.

The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto.

Vincent MD.

Evolution. 2010 Apr 1;64(4):1173-83. doi: 10.1111/j.1558-5646.2009.00942.x.

PMID:
20059538
21.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L.

J Clin Oncol. 2010 Jan 1;28(1):49-55. doi: 10.1200/JCO.2009.22.9427. Epub 2009 Nov 16.

PMID:
19917841
22.
23.

The price function of toxicity.

Vincent MD, Dranitsaris G.

Lancet Oncol. 2009 Mar;10(3):299-303. doi: 10.1016/S1470-2045(09)70067-1.

PMID:
19261259
24.

Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene.

Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD.

Cancer Lett. 2009 Feb 18;274(2):279-89. doi: 10.1016/j.canlet.2008.09.021. Epub 2008 Nov 4.

PMID:
18986763
25.

Balancing risk and benefit for first-line treatment of metastatic colorectal cancer: a graphic communication tool for patients and physicians.

Sanatani MS, Vincent MD.

Support Cancer Ther. 2007 Jan 1;4(2):101-9. doi: 10.3816/SCT.2007.n.004.

PMID:
18632474
26.

ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines.

Jason TL, Figueredo R, Ferguson PJ, Vincent MD, Berg RW, Koropatnick J.

DNA Cell Biol. 2008 May;27(5):229-40. doi: 10.1089/dna.2007.0674.

PMID:
18358073
28.

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.

Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD, Wong R.

Curr Oncol. 2007 Feb;14(1):13-20.

29.

Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.

Flynn J, Berg RW, Wong T, van Aken M, Vincent MD, Fukushima M, Koropatnick J.

Mol Cancer Ther. 2006 Jun;5(6):1423-33.

30.

Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment?

Videtic GM, Truong PT, Ash RB, Yu EW, Kocha WI, Vincent MD, Tomiak AT, Dar AR, Whiston F, Stitt LW.

Can Respir J. 2005 Jul-Aug;12(5):245-50.

31.

Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.

Videtic GM, Campbell C, Vincent MD.

Can Respir J. 2003 Apr;10(3):143-4.

32.

Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival.

Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD, Yu EW.

J Clin Oncol. 2003 Apr 15;21(8):1544-9.

PMID:
12697879
33.

A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.

Berg RW, Ferguson PJ, Vincent MD, Koropatnick DJ.

Cancer Gene Ther. 2003 Apr;10(4):278-86.

PMID:
12679800
34.

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE.

J Clin Oncol. 2002 Sep 1;20(17):3605-16.

PMID:
12202661
35.

Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Ferguson PJ, DeMoor JM, Vincent MD, Koropatnick J.

Br J Pharmacol. 2001 Dec;134(7):1437-46.

36.

Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control.

Videtic GM, Fung K, Tomiak AT, Stitt LW, Dar AR, Truong PT, Yu EW, Vincent MD, Kocha WI.

Lung Cancer. 2001 Aug-Sep;33(2-3):249-58.

PMID:
11551420
38.

Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.

Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, Koropatnick J.

Br J Pharmacol. 1999 Aug;127(8):1777-86.

39.

Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.

Videtic GM, Fisher BJ, Perera FE, Bauman GS, Kocha WI, Taylor M, Vincent MD, Plewes EA, Engel CJ, Stitt LW.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):319-24.

PMID:
9788410
40.

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

Obrocea MM, Nassim MA, Molepo MJ, Shirazi FH, Gallant G, Dulude H, Vincent MD, Stewart DJ, Goel R.

Oncol Rep. 1998 Nov-Dec;5(6):1493-8.

PMID:
9769394
41.

Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription.

DeMoor JM, Vincent MD, Collins OM, Koropatnick J.

Exp Cell Res. 1998 Aug 25;243(1):11-21.

PMID:
9716444
42.

Superior vena cava obstruction in small-cell lung cancer.

Chan RH, Dar AR, Yu E, Stitt LW, Whiston F, Truong P, Vincent MD, Kocha WI.

Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):513-20.

PMID:
9231674
43.
44.

Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging.

Vincent MD, Ashley SE, Smith IE.

Eur J Cancer Clin Oncol. 1987 Nov;23(11):1589-99.

PMID:
2828070
45.

The definition of a neoplasm.

Vincent MD.

Med Hypotheses. 1987 Oct;24(2):151-60.

PMID:
3316945
46.

Failure of iodine-131 MIBG imaging in small cell lung carcinoma.

Vincent MD, Babich J, Irvine A, McCready VR, Smith IE.

J Nucl Med. 1987 Jul;28(7):1230. No abstract available.

47.

Excision of solitary lung metastases from two patients with breast cancer.

Vincent MD, Powles TJ, Ford HT, Gazet JC.

Br J Surg. 1987 Mar;74(3):194. No abstract available.

PMID:
3567509
48.

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.

Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT.

J Clin Oncol. 1987 Feb;5(2):185-9.

PMID:
3027268
49.
50.

An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer.

Vincent MD, Powles TJ, Skeet R, Ashley S, Coombes RC, Gibb J, Clarke S, Thomas HL, Adcock H.

Eur J Cancer Clin Oncol. 1986 Sep;22(9):1059-65.

PMID:
3780813

Supplemental Content

Loading ...
Support Center